Krystal Biotech Reports $107M VYJUVEK Revenue for Q4 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3h ago
0mins
Source: Globenewswire
- Strong Financial Performance: Krystal Biotech anticipates Q4 2025 VYJUVEK net revenue between $106 million and $107 million, with full-year revenue expected between $388 million and $389 million, highlighting robust growth potential in the rare disease market.
- Clinical Pipeline Expansion: The company plans to accelerate clinical development for KB801 in 2026, increasing the enrollment target for its registrational study from 27 to 60 patients, aiming to expedite treatment for neurotrophic keratitis and solidify its market position in rare diseases.
- Clear Strategic Vision: Krystal Biotech aims to launch at least four rare disease medicines by the end of 2030, potentially benefiting over 10,000 patients, demonstrating its commitment and capability to address global treatment gaps in rare diseases.
- Ongoing R&D Investment: The company expects non-GAAP R&D and SG&A expenses to range from $175 million to $195 million in 2026, indicating a continued strategic investment in its clinical pipeline and larger indication projects to support long-term growth.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 248.910
Low
198.00
Averages
221.00
High
255.00
Current: 248.910
Low
198.00
Averages
221.00
High
255.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
